A clinical study shows that the level of circulating CD34/prominin-1(CD133)/VEGFR-2-triple positive vascular endothelial progenitor cells are significantly increased in stroke patients receiving NBP treatment compared with controls [18]. This evidence concerns the gene PROM1 and stroke disorder.